GlassScriptPhysician profile
James L Cimera
NPI 1578537791
$6,747.87
in general payments reported to CMS, 2019-2025
45 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $322 · 2021: $812 · 2022: $1,355 · 2023: $1,003 · 2024: $963 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.78 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Janssen Pharmaceuticals, INC | $1,026.35 | 2021-2023 | Ponvory |
| Ucb, INC. | $534.80 | 2019-2024 | Briviact, Nayzilam |
| Amgen INC. | $326.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $288.40 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $266.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $235.27 | 2019-2025 | Ultomiris |
| Pfizer INC. | $235.12 | 2023-2025 | |
| Genzyme Corporation | $187.52 | 2019-2022 | |
| Lilly USA, LLC | $177.50 | 2020-2024 | Amyvid |
| Sk Life Science, INC. | $177.30 | 2020-2025 | |
| Biogen, INC. | $175.50 | 2019-2023 | Vumerity, Tysabri |
| Portola Pharmaceuticals, LLC | $159.01 | 2019-2020 | |
| Emd Serono, INC. | $156.81 | 2019-2021 | |
| Acorda Therapeutics, INC | $142.35 | 2019-2023 | Inbrija |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cimera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.